CompletedPhase 2NCT00068393
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- Naomi S. Balzer-Haas, MDFox Chase Cancer Center
- Intervention
- Doxorubicin(drug)
- Enrollment
- 39 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2011
Study locations (30)
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States
- Rush-Copley Cancer Care Center, Aurora, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
- Hematology and Oncology Associates, Chicago, Illinois, United States
- Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
- Mercy Hospital and Medical Center, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Midwest Center for Hematology/Oncology, Joliet, Illinois, United States
- Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States
- North Shore Oncology and Hematology Associates, Limited - Libertyville, Libertyville, Illinois, United States
- Cancer Care and Hematology Specialists of Chicagoland - Niles, Niles, Illinois, United States
- Hematology Oncology Associates - Skokie, Skokie, Illinois, United States
- Hematology/Oncology of the North Shore at Gross Point Medical Center, Skokie, Illinois, United States
- Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00068393 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →